Verseon

The European Patent Office recently granted patent protection for our plasma (PK) inhibitors. PK is a validated target in diabetic (DR) and diabetic macular edema (DME), chronic diseases that lead to a form of vision loss associated with . Inhibiting PK also holds promise as a treatment for hereditary angioedema ( ), a potentially fatal condition characterized by severe swelling.

Verseon Receives European Patent for Innovative Compounds Covered compounds could provide revolutionary oral treatments for several chronic and fatal conditions

“Integrating AI and molecular modeling is likely to produce far more powerful breakthroughs in small molecule drug discovery than either approach could individually.”

Why AI Alone Cannot Find Tomorrow’s Medicines "AI is good at interpolating features within the bounds of a well-explored pool of training data but unable to make useful extrapolations far outside it."